Abstract 177P
Background
Clinical trials of combined LEN and anti-PD-1 antibodies in advanced HCC have shown promising anti-tumor effects. Although responses of both intra- and extra-hepatic tumors are typically evaluated to assess efficacy of a systemic therapy in HCC, the responses of tumors in different sites or organs can be very heterogeneous.
Methods
A retrospective analysis of patients with advanced, unresectable HCC who received 1L LEN (8 mg/d regardless of bodyweight) plus anti-PD-1 antibodies either q2wk (nivolumab or camrelizumab) or q3wk (pembrolizumab, sintilimab or toripalimab). Patients who completed ≥1 efficacy and safety assessment were eligible for inclusion. Overall objective response rate (ORR) and organ-specific response rate (OSRR) were assessed using RECIST 1.1 and mRECIST. All evaluations were repeated by an independent imaging reviewer.
Results
From Oct 2018 to Mar 2020, 59 patients were assessable for efficacy (median age: 54.3 years; 91.5% males). Among these patients, 2 (3.4%) were BCLC stage A, 11 (18.6%) were BCLC stage B, and 46 (78.0%) were BCLC stage C (including 30 with macroscopic vascular invasion, [China Liver Cancer [CNLC] stage IIIa] and 16 with extrahepatic metastasis or combined with macroscopic vascular invasion [CNLC stage IIIb]). The overall ORR evaluated using RECIST 1.1 and mRECIST was 32.2% and 57.6% according to investigator review, and 33.9% and 50.8% according to independent imaging review, respectively. OSRR was higher in macrovascular tumor thrombi (MVTT, including portal vein and hepatic veins) versus other sites (Table). Five patients with MVTT were successfully converted to liver resection because of downstaging via significant response in MVTT. Table: 177P
Objective response rate, % | RECIST v1.1 (investigator) | RECIST v1.1 (independent imaging review) |
Overall (n=59) | 32.2 | 33.9 |
Organ-specific | ||
Liver (n=57) | 33.0 | 32.0 |
Macrovascular tumor thrombi (n=33) | 57.5 | 51.5 |
Lung (n=7) | 37.5 | 37.5 |
Lymph node (n=6) | 33.3 | 33.3 |
Adrenal gland (n=2) | 100 | 100 |
Intra-abdominal implantation (n=2) | 100 | 100 |
Conclusions
The response of MVTT to combined LEN and anti-PD-1 antibodies was higher versus HCC tumors in other sites. The mechanisms underlying this differential response warrant further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
14P - BRCA mutation and clinical outcomes in breast cancer focusing on survivals and failure patterns: A long-term follow-up study of Koreans
Presenter: Hakyoung Kim
Session: e-Poster Display Session
15P - Designing of multimodal targeted tumor-seeking nanomedicine for triple-therapeutic effect
Presenter: Vellingiri Yasothamani
Session: e-Poster Display Session
16P - Topical henna cream in prevention of radiation-induced dermatitis in breast cancer: A randomized double-blind clinical trial
Presenter: Mansour Lesan
Session: e-Poster Display Session
17P - Comparison of dose distribution in the postoperative breast cancer patients irradiated with the technique of deep inspiratory breath hold and dynamic techniques
Presenter: Ewa Telka
Session: e-Poster Display Session
18P - A prospective randomized study comparing cosmetic outcome of sequential electron boost versus simultaneous integrated boost with IMRT to lumpectomy cavity during adjuvant radiotherapy to breast following BCS in carcinoma breast in Indian patients
Presenter: Sravya Bommera
Session: e-Poster Display Session
19P - Musculoskeletal pain and health-related quality of life among breast cancer patients
Presenter: Aslin Valiyagath
Session: e-Poster Display Session
20P - Molecular parallelisms and divergences between human and canine cancers
Presenter: Sadaf Ambreen
Session: e-Poster Display Session
21P - Neoadjuvant trastuzumab and pertuzumab in real-world data population in two medical institutions in Portugal
Presenter: Isabel Gomes Fernandes
Session: e-Poster Display Session
22P - Correlation of muscle strength and quality of life in Indonesian breast cancer patients who underwent chemotherapy
Presenter: Devina Halim
Session: e-Poster Display Session
23P - Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy: Follow up based on TAILORx study
Presenter: Faroug Ali
Session: e-Poster Display Session